Sort
39,280 grants matching “leukemia”
MYB family alterations in pediatric gliomas
$554,504Keith L Ligon · Dana-Farber Cancer Inst · R01 · FY2018 · CA
MYB family alterations in pediatric gliomas
$554,504Keith L Ligon · Dana-Farber Cancer Inst · R01 · FY2017 · CA
MYB family alterations in pediatric gliomas
$554,504Keith L Ligon · Dana-Farber Cancer Inst · R01 · FY2021 · CA
MYB family alterations in pediatric gliomas
$554,504Keith L Ligon · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer
$554,502Wei Li · University Of Tennessee Health Sci Ctr · R01 · FY2020 · CA
LEARNING IMPAIRMENTS AMONG SURVIVORS OF CHILDHOOD CANCER
$554,450St. Jude Children'S Research Hospital · R01 · FY2001 · CA
Animal models to study the role of INK4b loss in human acute myeloid leukemia
$554,313Linda Wolff · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Epigenetic Control of Hematopoietic Stem Cells
$554,313Christa E. Muller-Sieburg · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2010 · DK
Missouri Valley Cancer Consortium CCOP
$554,200Gamini Soori · Cancer Alliance Of Nebraska · U10 · FY2013 · CA
Biochemistry of Leukemia Virus Core Binding Factor
$554,199Nancy Asmussen Speck · University Of Pennsylvania · R01 · FY2017 · HL
Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML
$554,143Muxiang Zhou · Emory University · R01 · FY2024 · CA
Biologic and Therapeutic Significance of miR-155 in AML
$554,107Guido Marcucci · Beckman Research Institute/City Of Hope · R01 · FY2017 · CA
The Antiproliferative Activities of Human Interferons
$554,055Kathryn Zoon · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
$553,948Craig Lewis Duvall · Vanderbilt University · R01 · FY2022 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
$553,873Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer
$553,842Christopher Vakoc · Cold Spring Harbor Laboratory · P01 · FY2018 · CA
AML mutation-guided drugging of DNA repair
$553,754Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2022 · CA
(PQC2) Localization as a determinant of cancer dormancy
$553,740Charles P Lin · Massachusetts General Hospital · R01 · FY2017 · CA
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
$553,684Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2015 · CA
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
$553,684Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2017 · CA
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
$553,684Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2016 · CA
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
$553,684Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2014 · CA
Role of H2AX and ATM in Suppression of Thymic Lymphomas
$553,367Frederick W Alt · Dana-Farber Cancer Inst · P01 · FY2007 · CA
CCR Genomics Core
$553,306Kathleen Hartman · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA
Artificial, Humanized Stem Cell Niches
$553,236Biju Parekkadan · Rutgers, The State Univ Of N.J. · R01 · FY2020 · EB